Coronavirus disease 19 (COVID-19) can have a severe presentation characterized by a dysregulated immune response requiring admission to the intensive care unit (ICU). Immunomodulatory treatments like tocilizumab were found to improve inflammatory markers and lung injury over time. We aim to evaluate the effectiveness of tocilizumab treatment on critically ill patients with severe COVID-19.
Tocilizumab: A retrospective multi-center cohort study of critically ill patients with COVID-19
ABIFINA congratula novo presidente da Academia Nacional de Farmácia